FibroGen Agreement with Regeneron to Evaluate FibroGen’s Immuno-Oncology Assets in Trials

 

• FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumors
• FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumors
• Both FG-3165 and FG-3175 have demonstrated complementary mechanisms of action with PD-1 inhibitors in preclinical studies

https://www.globenewswire.com/news-release/2024/06/03/2892583/33525/en/FibroGen-Announces-Clinical-Trial-Supply-Agreement-with-Regeneron-Pharmaceuticals-to-Evaluate-FibroGen-s-Immuno-Oncology-Assets-FG-3165-anti-Galectin-9-and-FG-3175-anti-CCR8-in-Com.html